UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2016-04, Vol.100, p.88-98

2016

Volltextzugriff (PDF)

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Critical reviews in oncology/hematology, 2014-01, Vol.89 (1), p.140-165

2014

Volltextzugriff (PDF)

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1248-1260

2016

Volltextzugriff (PDF)

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient

European journal of cancer (1990), 2018-05, Vol.95, p.130-132

2018

Volltextzugriff (PDF)

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Cancer treatment reviews, 2016-09, Vol.49, p.1-12

2016

Volltextzugriff (PDF)

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

Journal of clinical oncology, 2018-12, Vol.36 (35), p.3441-3449

2018

Volltextzugriff (PDF)

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Cancer treatment reviews, 2020-08, Vol.88, p.102060-102060, Article 102060

2020

Volltextzugriff (PDF)

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab

European journal of cancer (1990), 2023-11, Vol.193, p.113320-113320, Article 113320

2023

Volltextzugriff (PDF)

Nras in melanoma: Targeting the undruggable target

Critical reviews in oncology/hematology, 2014-11, Vol.92 (2), p.107-122

2014

Volltextzugriff (PDF)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Journal of clinical oncology, 2022-12, Vol.40 (36), p.4178-4188

2022

Volltextzugriff (PDF)

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

European journal of cancer (1990), 2021-05, Vol.148, p.371-381

2021

Volltextzugriff (PDF)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Journal of clinical oncology, 2022-05, Vol.40 (13), p.1428-1438

2022

Volltextzugriff (PDF)

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Cancer treatment reviews, 2021-05, Vol.96, p.102190-102190, Article 102190

2021

Volltextzugriff (PDF)

Targeting BRAF in melanoma: Biological and clinical challenges

Critical reviews in oncology/hematology, 2013-09, Vol.87 (3), p.239-255

2013

Volltextzugriff (PDF)

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Current oncology reports, 2018-11, Vol.20 (11), p.86-16, Article 86

2018

Volltextzugriff (PDF)

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

Cancer treatment reviews, 2021-11, Vol.100, p.102280-102280, Article 102280

2021

Volltextzugriff (PDF)

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Seminars in cancer biology, 2022-11, Vol.86 (Pt 2), p.477-490

2022

Volltextzugriff (PDF)

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

JNCI : Journal of the National Cancer Institute, 2015-07, Vol.107 (7), p.djv171-djv171

2015

Volltextzugriff (PDF)

AKT-ions with a TWIST between EMT and MET

Oncotarget, 2016-09, Vol.7 (38), p.62767-62777

2016

Volltextzugriff (PDF)

Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group

European journal of cancer (1990), 2023-08, Vol.189, p.112921-112921, Article 112921

2023

Volltextzugriff (PDF)

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

Oncotarget, 2017-02, Vol.8 (9), p.15894-15911

2017

Volltextzugriff (PDF)

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Clinical cancer research, 2021-09, Vol.27 (17), p.4737-4745

2021

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(139)
Buchkapitel
(14)
Bücher
(2)

Sprache

Englisch
(155)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab

Nras in melanoma: Targeting the undruggable target

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Treatment of venous thromboembolism in cancer patients: The dark side of the moon

Targeting BRAF in melanoma: Biological and clinical challenges

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

AKT-ions with a TWIST between EMT and MET

Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Aktive Filter

Suchergebnisse filtern